We are a biopharmaceutical company using our proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Our primary focus is oncology (cancer) but our technology may also have applications in the discovery of new therapeutics for infectious diseases, including COVID-19.
Our leading discovery program targets interleukin-38, a small protein,secreted by various cells of the body, which appears to function as a novel immune checkpoint inhibitor.
We entered into an agreement with the U.S. Department of Defense in July 2020 to develop a BCP product candidate for the potential treatment and prevention of SARS-CoV-2 infections, including COVID-19. (BCP is an acronym for biosynthetic convalescent plasma.)
|Address||665 Stockton Drive, Suite 300 Exton, PA 19341|
|Phone Number||(610) 321-3700|
|View Prospectus:||Immunome, Inc.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-8.5 mil (last 12 months)|
|Price range||$0.00 - $0.00|
|Est. $ Volume||$30.0 mil|
|Manager / Joint Managers||Ladenburg Thalmann/ Chardan|
|Expected To Trade:|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|